Concepedia

Author

N. Horvath

Case Western Reserve University

Also Known As

N HORVATH, N Horvath, N. Horvath, N. J. Horvath, NOEMI HORVATH, Nancy Horvath

23

Publications

835

Citations

10

H-Index

26

Concepts

All Affiliations

Case Western Reserve UniversityUniversity Hospitals Cleveland Medical Center
NH

About

N. Horvath is an author at Case Western Reserve University specializing in medicine, dermatology, and allergy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

243

2

Social Sciences

1

1

56

3

Allergy

1

1

38

4

Allergy Medicine

1

1

38

5

Neurology

1

1

56

N. Horvath

×

9

Publications

800

Citations

9

H-Index

YearCitations

Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.

Luen Bik To, Marion M. Roberts, David N. Haylock,

PubMed

1992

414

Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential

Minakshi Nihal, Debra Mikkola, N. Horvath,

Human Pathology

2003

126

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

Harry Iland, K. F. Bradstock, John F. Seymour,

Haematologica

2011

59

THE INCORPORATION OF <sup>14</sup>C DERIVED FROM GLUCOSE INTO THE PROTEINS OF THE BRAIN CORTEX, AT REST AND DURING ACTIVITY*

A. Geiger, N. Horvath, Yukio Kawakita

Journal of Neurochemistry

1960

56

The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia.

To Lb, Haylock Dn, D Thorp,

PubMed

1989

47

Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis

Geeta Mohla, N. Horvath, Seth R. Stevens

Journal of the American Academy of Dermatology

1999

38

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

Sharon L. Sanborn, Joseph Gibbons, Smitha Krishnamurthi,

Investigational New Drugs

2008

23

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma

Paul M. Barr, Pingfu Fu, Hillard M. Lazarus,

British Journal of Haematology

2009

21

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen A. O’Connor, James R. Wright, Craig H. Moskowitz,

Blood

2004

16

Page 1